한글목차

약제 요약

Pfizer에서 임상시험중인 RSV 백신 후보물질인 ABRYSVO(RSVpreF)는 RSV가 인간 세포를 공격하는 데 사용하는 바이러스 융합 단백질(F)의 주요 형태인 프리퓨전 F의 결정구조를 상세하게 설명한 NIH 연구 등 기초과학의 기초적인 발견을 기반으로 하고 있습니다. NIH 연구는 프리퓨전에 특이적인 항체가 바이러스 감염을 막는 데 매우 효과적이라는 것을 보여주었고, 프리퓨전 F를 기반으로 한 백신이 RSV에 대한 최적의 방어력을 제공할 수 있다는 것을 보여주었습니다. 이 중요한 발견 이후 화이자는 이 바이러스 단백질의 여러 버전을 테스트하고 전임상 평가에서 강력한 항바이러스 면역 반응을 유발하는 버전을 확인했습니다. 이 백신 후보는 RSV A와 B에 대한 방어력을 최적화하기 위해 선택된 두 개의 preF 단백질로 구성되어 있습니다.

주요 7 시장(미국·독일·프랑스·이탈리아·스페인·영국·일본)의 호흡기세포융합바이러스(RSV)용 ABRYSVO에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동에 관한 인사이트, 매출의 예측 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 RSV에서의 ABRYSVO 개요

• 제품의 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 신치료법)

제5장 ABRYSVO 시장 평가

• RSV에서 ABRYSVO의 시장 전망
• 주요 7 시장 분석
  • 주요 7 시장 RSV용 ABRYSVO의 시장 규모
• 시장 분석 : 국가별
  • 미국의 RSV용 ABRYSVO의 시장 규모
  • 독일의 RSV용 ABRYSVO의 시장 규모
  • 영국의 RSV용 ABRYSVO의 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

"ABRYSVO Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about ABRYSVO for Respiratory syncytial virus (RSV) in the seven major markets. A detailed picture of the ABRYSVO for RSV in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ABRYSVO for RSV. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ABRYSVO market forecast analysis for RSV in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.

Drug Summary:

Pfizer's investigational RSV vaccine candidate, ABRYSVO (RSVpreF), builds on foundational basic science discoveries, including those made at the National Institutes of Health (NIH), which detailed the crystal structure of prefusion F, a key form of the viral fusion protein (F) that RSV uses to attack human cells. The NIH research showed that antibodies specific to the prefusion form were highly effective at blocking virus infection, suggesting a prefusion F-based vaccine may confer optimal protection against RSV. After this important discovery, Pfizer tested numerous versions of the viral protein and identified those that elicited a strong antiviral immune response in preclinical evaluation. The vaccine candidate comprises two preF proteins selected to optimize protection against RSV A and B. Currently, the company is investigating this vaccine in many Phase III clinical trials.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ABRYSVO description, mechanism of action, dosage and administration, research and development activities in Respiratory syncytial virus (RSV).
• Elaborated details on ABRYSVO regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ABRYSVO research and development activities in RSV across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ABRYSVO.
• The report contains forecasted sales of ABRYSVO for RSV till 2032.
• Comprehensive coverage of the late-stage emerging therapies for RSV.
• The report also features the SWOT analysis with analyst views for ABRYSVO in RSV.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ABRYSVO Analytical Perspective by DelveInsight

• In-depth ABRYSVO Market Assessment

This report provides a detailed market assessment of ABRYSVO for Respiratory syncytial virus (RSV) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• ABRYSVO Clinical Assessment

The report provides the clinical trials information of ABRYSVO for RSV covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Respiratory syncytial virus (RSV) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ABRYSVO dominance.
• Other emerging products for RSV are expected to give tough market competition to ABRYSVO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ABRYSVO in RSV.
• Our in-depth analysis of the forecasted sales data of ABRYSVO from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ABRYSVO in RSV.

Key Questions:

• What is the product type, route of administration and mechanism of action of ABRYSVO?
• What is the clinical trial status of the study related to ABRYSVO in Respiratory syncytial virus (RSV) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ABRYSVO development?
• What are the key designations that have been granted to ABRYSVO for RSV?
• What is the forecasted market scenario of ABRYSVO for RSV?
• What are the forecasted sales of ABRYSVO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ABRYSVO for RSV?
• Which are the late-stage emerging therapies under development for the treatment of RSV?

Table of Contents

1. Report Introduction

2. ABRYSVO Overview in RSV

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. ABRYSVO Market Assessment

• 5.1. Market Outlook of ABRYSVO in RSV
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of ABRYSVO in the 7MM for RSV
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of ABRYSVO in the United States for RSV
  • 5.3.2. Market Size of ABRYSVO in Germany for RSV
  • 5.3.3. Market Size of ABRYSVO in France for RSV
  • 5.3.4. Market Size of ABRYSVO in Italy for RSV
  • 5.3.5. Market Size of ABRYSVO in Spain for RSV
  • 5.3.6. Market Size of ABRYSVO in the United Kingdom for RSV
  • 5.3.7. Market Size of ABRYSVO in Japan for RSV

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options